{"meta":{"query_hash":"08c60bd9815f","filters":{"venue":"Core evidence"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/08c60bd9815f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Core+evidence"},"results":[{"id":"W1972864082","doi":"10.2147/ce.s42568","title":"An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies","year":2013,"lang":"en","type":"article","venue":"Core evidence","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacology; Leukemia; Lymphoma; Adverse effect; Venetoclax; Oncology; Cancer research; Immunology; Chronic lymphocytic leukemia","score_opus":0.07430101011301232,"score_gpt":0.3242971822992617,"score_spread":0.24999617218624937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972864082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8770779,0.12138837,0.00043628985,0.0004529028,0.00003507374,0.00057982106,0.0000015814867,0.0000032127205,0.000024863843],"genre_scores_gemma":[0.9240089,0.07508575,0.00050771213,0.00024740509,0.000022662922,0.00008212469,0.000010696261,0.000004082785,0.000030674546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99918485,0.00010798023,0.0002707262,0.00018870561,0.00014091321,0.00010684989],"domain_scores_gemma":[0.99921566,0.00008084899,0.00013774204,0.00041715437,0.0001218167,0.000026781621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026583736,0.0000981915,0.00019508618,0.000019339734,0.000019204706,0.0000062472454,0.00020246567,0.00007048441,0.00006988938],"category_scores_gemma":[0.00015851243,0.000055133693,0.00008872261,0.00010559606,0.00007997737,0.000010855006,0.000013462994,0.000021678905,0.000004167325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005507541,0.00024540562,0.010603971,0.0013757673,0.000011388181,0.0000054553543,0.00010850363,0.00007139411,0.97308403,0.0007373921,0.00040435733,0.013297281],"study_design_scores_gemma":[0.0005491564,0.0058706496,0.0764365,0.020330599,0.00010268004,0.00003901111,0.00017893482,0.0013587837,0.89067245,0.0009773994,0.0031267696,0.00035706777],"about_ca_topic_score_codex":0.00006168081,"about_ca_topic_score_gemma":0.000011238807,"teacher_disagreement_score":0.08241156,"about_ca_system_score_codex":0.000010934134,"about_ca_system_score_gemma":0.00005948175,"threshold_uncertainty_score":0.22482868},"labels":[],"label_agreement":null},{"id":"W2044171598","doi":"10.2147/ce.s40698","title":"Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","year":2014,"lang":"en","type":"review","venue":"Core evidence","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Shared Health","funders":"","keywords":"Ceftazidime/avibactam; Avibactam; Ceftazidime; Medicine; Pharmacology; Tolerability; Microbiology; Pseudomonas aeruginosa; Adverse effect; Biology","score_opus":0.12105615346282708,"score_gpt":0.4038837467701463,"score_spread":0.2828275933073192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044171598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058903623,0.93859714,0.00008619725,0.000052427527,0.00045765814,0.0017966201,0.00009502832,0.000006146558,0.00000517192],"genre_scores_gemma":[0.011632183,0.98720723,0.00029350608,0.000119267235,0.00033814542,0.00012569864,0.00020762753,0.00003359687,0.000042752563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965745,0.0013047359,0.0009766851,0.00065247476,0.00021723784,0.00027431664],"domain_scores_gemma":[0.9970358,0.0008150409,0.0009969808,0.00078912626,0.00027831824,0.00008473518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066546246,0.00046668935,0.0014718279,0.00010993315,0.00006282454,0.00003336864,0.0004944192,0.00034125123,0.00008654302],"category_scores_gemma":[0.001214534,0.00031848616,0.0003982852,0.00029035617,0.00040678238,0.000038513765,0.00007714194,0.00016364218,0.0000051516836],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015688528,0.003533335,0.0042698574,0.36500037,0.0013959957,0.00007727457,0.0003850399,0.000015631964,0.118740484,0.000115082694,0.0057040406,0.49919406],"study_design_scores_gemma":[0.00074036384,0.0037895895,0.0015032655,0.19532903,0.0025851196,0.00008274556,0.000011132977,0.0000056463564,0.0028188021,0.000007854241,0.7924533,0.0006731414],"about_ca_topic_score_codex":0.00005833458,"about_ca_topic_score_gemma":0.000093712966,"teacher_disagreement_score":0.7867493,"about_ca_system_score_codex":0.000064333384,"about_ca_system_score_gemma":0.000530493,"threshold_uncertainty_score":0.99992675},"labels":[],"label_agreement":null},{"id":"W2060750200","doi":"10.2147/ce.s7031","title":"Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease","year":2009,"lang":"en","type":"article","venue":"Core evidence","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Entacapone; Dyskinesia; Levodopa; Carbidopa; Parkinson's disease; Medicine; Tolerability; Ropinirole; Adverse effect; Aromatic L-amino acid decarboxylase; Dopamine; Pramipexole; Pharmacology; Catechol-O-methyl transferase; Anesthesia; Internal medicine; Disease; Chemistry","score_opus":0.18869641609488635,"score_gpt":0.39317053505880145,"score_spread":0.2044741189639151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060750200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401821,0.050545383,0.00015568986,0.006011162,0.0001899426,0.00274519,0.00005746493,0.000037358608,0.000075741],"genre_scores_gemma":[0.9916124,0.0057017934,0.000251644,0.0010893063,0.00019775765,0.00048610277,0.000021801503,0.000019529938,0.0006197171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979407,0.00014463461,0.00039147894,0.0005292944,0.0005688157,0.00042503473],"domain_scores_gemma":[0.99714667,0.001344272,0.00018652358,0.0009476536,0.00013764421,0.00023724115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004253005,0.00032078064,0.00041492723,0.00009037793,0.0001587151,0.00003657305,0.00039526387,0.000062182145,0.000053722153],"category_scores_gemma":[0.00096042024,0.00017221642,0.00029461493,0.0003824774,0.00008704732,0.00021280385,0.000022687173,0.00010364352,0.000040353505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03629986,0.016339077,0.7153715,0.0017552967,0.0008189988,0.0023451261,0.015931966,0.00049118954,0.020725816,0.0074301427,0.018718489,0.16377255],"study_design_scores_gemma":[0.0039254734,0.003567373,0.93342847,0.0032958495,0.0013568266,0.0000555826,0.00031700596,0.001609912,0.0032691488,0.0012528282,0.047542237,0.0003792915],"about_ca_topic_score_codex":0.00006355194,"about_ca_topic_score_gemma":0.000050019233,"teacher_disagreement_score":0.21805699,"about_ca_system_score_codex":0.00025919944,"about_ca_system_score_gemma":0.00030189374,"threshold_uncertainty_score":0.70227814},"labels":[],"label_agreement":null},{"id":"W2793091729","doi":"10.2147/ce.s133661","title":"Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis","year":2018,"lang":"en","type":"review","venue":"Core evidence","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University; University of British Columbia","funders":"","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology","score_opus":0.18114665579964437,"score_gpt":0.41802296174934195,"score_spread":0.23687630594969758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793091729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005159703,0.99659556,0.000008026322,0.00044141078,0.00018975901,0.0021413555,0.00002567248,0.000015422705,0.000066837085],"genre_scores_gemma":[0.0040216194,0.9946131,0.000066266075,0.0007568766,0.00013943168,0.00026907562,0.000058532467,0.000019886824,0.00005521911],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99713635,0.00070227723,0.0011103781,0.00038291412,0.00044209557,0.00022598573],"domain_scores_gemma":[0.99676955,0.0010831136,0.0006934155,0.0010906514,0.00026269795,0.00010059127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043787935,0.00035108926,0.0021650128,0.0001610672,0.000039920797,0.00000766704,0.00051917665,0.00021529473,0.0003561838],"category_scores_gemma":[0.0013083469,0.00020540193,0.0006623595,0.0004614885,0.00030196641,0.00018798353,0.000027364902,0.00015438342,0.000066715846],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003653354,0.0007095988,0.001836948,0.56632215,0.00013250162,0.0006127906,0.0001225381,1.4201085e-7,5.8595185e-7,0.00004227982,0.009329083,0.42085484],"study_design_scores_gemma":[0.0002675848,0.00064126984,0.0030697908,0.72606456,0.0028383574,0.00027442016,0.000009253567,0.000009390251,0.00001199325,0.000012306582,0.26664704,0.00015404291],"about_ca_topic_score_codex":0.000024635156,"about_ca_topic_score_gemma":0.000012207253,"teacher_disagreement_score":0.4207008,"about_ca_system_score_codex":0.0000925436,"about_ca_system_score_gemma":0.0010039147,"threshold_uncertainty_score":0.83760476},"labels":[],"label_agreement":null}]}